MedTrace Logo

Inhalative Sedation in ICU With Sevoflurane Via Anaesthetic Conserving Device Compared to Propofol

NCT00586118 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2008-01-04

No results posted yet for this study

Summary

The evaluation of the presented study will work on the practicability of inhalative sedation on the ICU, potential benefits and limitations of the ACD system in a postoperative sedated patient population in comparison to a standard intravenous sedation regimen with propofol, and focus on renal and hepatic function, cardioprotection and pharmacoeconomics

Conditions

  • Recovery From Sedation
  • Sevoflurane Consumption
  • Renal Function
  • Hepatic Function
  • Cardioprotection

Interventions

DRUG

Sevoflurane

Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU

DRUG

Propofol

Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours

Sponsors & Collaborators

  • Universitätsmedizin Mannheim

    collaborator OTHER

  • Klinikum Ludwigshafen

    lead OTHER

Principal Investigators

  • Kerstin D. Röhm, Dr. med. · Klinikum Ludwigshafen, Department of Anaesthesiology, Ludwigshafen, Germany

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2007-12-31
Completion
2007-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00586118 on ClinicalTrials.gov